Drug
Taliglucerase alfa clinical trials
Also written Elelyso and PRX-112.
- studies test it
- 12
- open now
- 0
- in phase 3
- 5
- first study started
- 2005
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 1
- Phase 3
- 5
- Phase 4
- 3
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 2
Pfizer (7) · Protalix (3) · Ari Zimran (1) · Shaare Zedek Medical Center (1)
Studies
Open first, then newest update. How each study uses taliglucerase alfa is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher DiseaseCompletedPhase 4Ari ZimranNCT04002830Written as Elelyso
- A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher DiseaseCompletedPhase 3PfizerNCT01422187Written as Taliglucerase alfa
- Assessing the Impact of Elelyso on Bone Involvement Currently Treated With Other ERTsCompletedNot applicableShaare Zedek Medical CenterNCT04353466Written as Elelyso
- Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) In Pediatric Subjects With Type 1 Gaucher DiseaseWithdrawnPhase 4PfizerNCT03021941Written as Elelyso 60 units/kg
- A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher DiseaseCompletedPhase 4PfizerNCT01132690Written as Taliglucerase alfa
- Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human GlucocerebrosidaseCompletedPhase 3PfizerNCT00712348Written as Taliglucerase alfa
- Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension TrialCompletedPhase 3PfizerNCT00705939Written as Taliglucerase alfa
- A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher DiseaseCompletedPhase 3PfizerNCT00376168Written as Plant cell expressed recombinant glucocerebrosidase (prGCD)
- A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher DiseaseCompletedPhase 3PfizerNCT01411228Written as Taliglucerase alfa
- An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112CompletedPhase 2ProtalixNCT02107846Written as PRX-112
- Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease PatientsCompletedPhase 1ProtalixNCT01747980Written as PRX-112
- Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)CompletedPhase 1ProtalixNCT00258778Written as Human Glucocerebrosidase (prGCD)
Codes
What other systems call taliglucerase alfa · ClinicalTrials.gg INT006317
- UNII (FDA) 0R4NLX88O4TALIGLUCERASE ALFAConfirmed FDA, Wikidata
- RxNorm 1291609One source FDA
- Wikidata Q7679506taliglucerase alfaConfirmed FDA, Wikidata
- NCI Thesaurus C97411Taliglucerase AlfaOne source FDA
- DrugBank DB08876One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 0R4NLX88O4 | TALIGLUCERASE ALFA | Confirmed FDA, Wikidata |
| RxNorm | 1291609 | — | One source FDA |
| Wikidata | Q7679506 | taliglucerase alfa | Confirmed FDA, Wikidata |
| NCI Thesaurus | C97411 | Taliglucerase Alfa | One source FDA |
| DrugBank | DB08876 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.